DEAGLIO, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 7.544
EU - Europa 5.686
AS - Asia 2.537
AF - Africa 151
SA - Sud America 34
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.980
Nazione #
US - Stati Uniti d'America 7.434
IT - Italia 1.780
CN - Cina 1.601
IE - Irlanda 729
SE - Svezia 597
DE - Germania 509
UA - Ucraina 498
KR - Corea 419
FR - Francia 387
FI - Finlandia 303
AT - Austria 265
GB - Regno Unito 201
VN - Vietnam 161
PL - Polonia 135
SN - Senegal 118
CA - Canada 102
IN - India 78
JP - Giappone 75
BE - Belgio 59
ES - Italia 46
SG - Singapore 40
NL - Olanda 33
HK - Hong Kong 32
CZ - Repubblica Ceca 27
IR - Iran 27
CH - Svizzera 23
TW - Taiwan 22
BY - Bielorussia 21
UZ - Uzbekistan 21
AU - Australia 19
BR - Brasile 16
PH - Filippine 15
EG - Egitto 14
GR - Grecia 12
RO - Romania 12
RU - Federazione Russa 12
NG - Nigeria 9
NO - Norvegia 8
TR - Turchia 8
LU - Lussemburgo 7
TH - Thailandia 7
AR - Argentina 6
ID - Indonesia 6
MX - Messico 6
PK - Pakistan 6
SA - Arabia Saudita 6
CL - Cile 5
DK - Danimarca 5
MO - Macao, regione amministrativa speciale della Cina 5
NZ - Nuova Zelanda 5
EU - Europa 4
HU - Ungheria 4
ZA - Sudafrica 4
EC - Ecuador 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
HR - Croazia 2
MA - Marocco 2
MY - Malesia 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
CO - Colombia 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
IL - Israele 1
IM - Isola di Man 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SI - Slovenia 1
Totale 15.980
Città #
Chandler 1.214
Beijing 923
Dublin 727
Torino 609
Houston 432
Fairfield 399
Ashburn 398
Ann Arbor 312
Jacksonville 287
Vienna 258
Nyköping 251
Wilmington 248
Villeurbanne 244
Medford 239
Princeton 237
Woodbridge 192
Dearborn 185
Cambridge 159
Turin 158
Seattle 136
Dong Ket 131
Milan 121
Warsaw 121
Redwood City 103
Boston 98
Fremont 86
New York 75
Shanghai 73
Guangzhou 67
Pisa 67
Nanjing 60
Centro 52
Boardman 51
San Mateo 51
Hangzhou 50
Norwalk 44
Brussels 42
Toronto 38
San Diego 37
Novara 34
Hefei 33
Falls Church 27
Kunming 26
Rome 26
Düsseldorf 23
Jinan 22
Xian 22
Ottawa 19
Verona 19
Mountain View 18
Tokyo 18
Wuhan 18
Washington 17
Lappeenranta 16
Los Angeles 16
Nanchang 16
Scilla 16
Seoul 16
Chengdu 15
Garessio 15
Singapore 15
Shenyang 14
Taipei 14
Upper Marlboro 14
Barcelona 13
Detroit 13
Hebei 13
Perugia 13
Philadelphia 13
Bologna 12
Fuzhou 12
Lachine 12
London 12
Munich 12
Paris 12
Belfast 11
Brookline 11
Pune 10
Zhengzhou 10
Central District 9
Changsha 9
Chennai 9
Florence 9
Phoenix 9
Redmond 9
San Francisco 9
Silver Spring 9
Vestignè 9
Abuja 8
Columbus 8
Helsinki 8
Marche 8
Naples 8
Nürnberg 8
Piemonte 8
Salvador 8
Tianjin 8
Amsterdam 7
Berlin 7
Chongqing 7
Totale 9.817
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 664
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. 443
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies 380
Subcellular characterization of NAD+ biosynthesis in metastatic melanoma by using organelle-specific biosensors 272
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22 264
Mir-214 and mir-148b targeting inhibits dissemination of melanoma and breast cancer 245
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 222
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 214
Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome 189
Extracellular nicotinate phosphoribosyltransferasebinds Toll like receptor 4 and mediatesinflammation 188
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 171
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 170
Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of patent WO2013063498. 165
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 155
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 154
Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience 154
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 144
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma 139
Targeting metabolism and survival in chronic lymphocytic leukemia and richter syndrome cells by a novel NF-κB inhibitor 134
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. 122
The genetics of nodal marginal zone lymphoma 122
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. 122
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation 118
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 113
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 112
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 112
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 111
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma 111
The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies 107
THE PD-1/PD-L1 AXIS CONTRIBUTES TO T CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 106
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 105
Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma 104
NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer 102
NOVEL AND KNOWN MUTATIONS IDENTIFIED BY CLINICAL EXOME SEQUENCING FOR THE DIAGNOSIS OF POLYCYSTIC KIDNEY DISEASE 102
NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. 99
Abstract 5170: Metabolism and cancer: The CD38-NAMPT connection in chronic lymphocytic leukemia 97
Immune response dysfunction in chronic lymphocytic leukemia: Dissecting molecular mechanisms and microenvironmental conditions 97
ASSOCIATION BETWEEN RS12917707 SINGLE NUCLEOTIDE POLYMORPHISM AT THE UMOD PROMOTER REGION AND SERUM UROMODULIN LEVELS: IMPLICATIONS IN KIDNEY TRANSPLANTATION 95
USE OF CLINICAL EXOME SEQUENCING IN THE DIAGNOSTIC FLOW OF MONOGENIC KIDNEY DISEASES: THE PIEDMONT EXPERIENCE 93
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 91
Abstract 2630: Nicotinamide activates the p53/miR-34a/SIRT1 tumor suppressor network leading to apoptosis of chronic lymphocytic leukemia cells 91
Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines 90
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 89
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential 88
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 87
Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia 87
BRAF-mediated NAMPT overexpression induces a melanoma cell dedifferentiation program leading to metabolic reprogramming and intrinsic resistant to BRAF inhibitors 86
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation 85
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression 84
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 84
Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. 84
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia 82
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? 82
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology 81
All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. 80
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells 80
Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia 80
CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity 79
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 78
Nampt over-expression recapitulates the braf inhibitor resistant phenotype plasticity in melanoma 78
CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. 77
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 77
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. 76
The heme exporter FLVCR1a modulates the tricarboxylic acid cycle: a new target in colorectal cancer 76
Targeting the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities 76
CD38 at the junction between prognostic marker and therapeutic target 75
A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. 75
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 75
HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity 75
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle 73
Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle. 73
CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus 72
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models 72
Cationization of monoclonal antibodies: another step towards the 'magic bullet'? 71
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle. 71
CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival 70
The hidden life of NAD+-consuming ectoenzymes in the endocrine system. 70
SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy 70
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. 70
Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. 70
Rapid and sensitive detection of recombinant soluble proteins in the supernatant of transfected mammalian cells. 69
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells 69
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 69
CD38 in chronic lymphocytic leukemia: from bench to bedside? 68
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22 68
Genome-Wide Study Updates in the International Genetics and Translational Research in Transplantation Network (iGeneTRAiN) 68
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia 67
Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT) 67
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. 67
Signaling and activation, calcium anc cytokine release, receptorial activities of the human CD38 family NAD+-converting enzymes 66
Structural, functional and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum 66
Loss of the heme exporter FLVCR1a impairs mitochondrial functionality: a new approach against colorectal cancer 66
Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism 66
CD38 Workshop Report 65
E2A is a transcriptional regulator of CD38 expression in chroniclymphocytic leukemia 65
Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia 65
HLA-DRB1 mismatch-based identification of donor-derived cell free DNA (dd-cfDNA) as a marker of rejection in heart transplant recipients: A single-institution pilot study. 65
B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter Transformation 64
Totale 11.285
Categoria #
all - tutte 48.680
article - articoli 0
book - libri 0
conference - conferenze 7.842
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.522


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019350 0 0 0 0 0 0 0 0 0 0 243 107
2019/20202.180 59 73 114 259 144 359 268 171 213 249 179 92
2020/20212.532 172 195 151 107 281 145 271 173 354 236 164 283
2021/20222.680 126 111 140 193 157 162 176 121 107 252 610 525
2022/20233.630 401 345 78 388 281 877 268 208 402 110 169 103
2023/20241.468 226 312 114 71 147 224 71 153 30 108 12 0
Totale 16.581